Shell PLC ADR (SHEL)vsVertex Pharmaceuticals Inc (VRTX)
SHEL
Shell PLC ADR
$83.97
-0.32%
ENERGY · Cap: $243.12B
VRTX
Vertex Pharmaceuticals Inc
$429.82
+1.13%
HEALTHCARE · Cap: $107.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Shell PLC ADR generates 2084% more annual revenue ($266.89B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 6.7%. SHEL appears more attractively valued with a PEG of 1.32. VRTX earns a higher WallStSmart Score of 66/100 (B-).
SHEL
Buy61
out of 100
Grade: C+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.5%
Fair Value
$84.58
Current Price
$83.97
$0.61 discount
Margin of Safety
+57.2%
Fair Value
$992.87
Current Price
$429.82
$563.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Reasonable price relative to book value
Earnings expanding 376.2% YoY
Attractively priced relative to earnings
Generating 1.6B in free cash flow
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 24 in profit
Areas to Watch
6.7% margin — thin
Weak financial health signals
Revenue declined 3.3%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : SHEL
The strongest argument for SHEL centers on Market Cap, Price/Book, EPS Growth. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : SHEL
The primary concerns for SHEL are Profit Margin, Piotroski F-Score, Revenue Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
SHEL profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.30 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
SHEL generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 61/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Shell PLC ADR
ENERGY · OIL & GAS INTEGRATED · USA
Shell plc is a global petrochemical and energy company. The company is headquartered in The Hague, the Netherlands.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other OIL & GAS INTEGRATED Stocks
Want to dig deeper into these stocks?